Granules India: Business Overview & Financial Analysis
Granules India is a prominent Indian vertically integrated pharmaceutical enterprise headquartered in Hyderabad, Telangana. The company operates across the entire pharmaceutical value chain, specialising in Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages (FDs). Serving global healthcare markets across North America, Europe, Latin America, and Asia-Pacific, Granules India provides off-patent finished formulations, high-volume generic APIs, and specialized formulation products backed by advanced manufacturing campuses in India and North America.
Revenue Breakdown by Product Category of Granules India (FY26)
Granules India derives its operational turnover across finished dosages, pharmaceutical formulation intermediates, and active pharmaceutical ingredients.
- Finished Dosages (FDs) – 54.0% of Total Operating Revenue
- Active Pharmaceutical Ingredients (APIs) – 26.0% of Total Operating Revenue
- Pharmaceutical Formulation Intermediates (PFIs) – 20.0% of Total Operating Revenue
- Total Consolidated Revenue from Operations (FY26) – Rs 4,850.40 crore (+8.5% YoY)
Finished Dosages constitute over half of total sales, representing the highest value-added segment within the pharmaceutical chain. APIs and PFIs provide integrated supply chain capabilities, supporting internal finished dosage production while catering to external global partners.
Core Molecules Portfolio & Revenue Share of Granules India (FY26)
Granules India commands global scale and market leadership across high-volume essential pharmaceutical molecules.
- Core Molecules Share (Paracetamol, Ibuprofen, Metformin, Methocarbamol, Guaifenesin) – 78.0% of Total Revenue
- Paracetamol Portfolio Share – 38.0% of Total Revenue
- Ibuprofen Portfolio Share – 18.0% of Total Revenue
- Metformin Portfolio Share – 12.0% of Total Revenue
- Other Core Molecules & Emerging Formulations Share – 32.0% of Total Revenue
Five key core molecules account for nearly four-fifths of operational turnover, with Paracetamol serving as the primary commercial anchor. High manufacturing scale and backward integration enable cost competitiveness across global off-patent tender markets.
Geographic Revenue Mix & Export Footprint of Granules India (FY26)
Granules India delivers pharmaceutical formulations and active ingredients to regulated western geographies and emerging international markets.
- North America (United States & Canada) – 62.0% of Total Revenue
- Europe – 18.0% of Total Revenue
- Latin America (LATAM) – 8.0% of Total Revenue
- India (Domestic Market) – 7.0% of Total Revenue
- Rest of the World (RoW) – 5.0% of Total Revenue
North America represents the primary commercial market, generating over six-tenths of total turnover through direct retail and institutional sales channels. European and Latin American distribution networks support market expansion for multi-dose combination products.
Manufacturing Infrastructure & USFDA Status of Granules India (FY26)
Granules India operates state-of-the-art manufacturing plants compliant with major international health regulatory authorities.
- Gagillapur Unit (Telangana) – World's largest single-site PFI and Finished Dosage facility
- Bonthapally Unit (Telangana) – Large-scale API manufacturing plant for Paracetamol
- Jeedimetla Unit (Telangana) – Specialized API and PFI processing plant
- Vizag Unit (AP SEZ) – API facility for Oncology and specialized active ingredients
- Chantilly Facility (Virginia, US) – R&D and specialized formulation manufacturing site
- USFDA Compliance Status – Key manufacturing facilities successfully cleared by USFDA with zero 483 observations
The integrated facility at Gagillapur operates as one of the world's largest single-site processing plants for PFIs and finished tablets. Regulatory approvals from the USFDA, UK MHRA, and EDQM support global export dispatches.
Intellectual Property & Regulatory Filings Pipeline of Granules India (Q4 FY26)
Granules India invests in R&D infrastructure to build a proprietary pipeline of Abbreviated New Drug Applications (ANDAs) and Drug Master Files (DMFs).
- Total Cumulative ANDA Filings with USFDA – 82 ANDA Filings
- Total Approved ANDA Products – 64 Approved ANDAs
- Active Commercialized ANDA Products in US – 52 Commercial Products
- Cumulative European Certificate of Suitability (CEP) Filings – 32 CEPs
- Annual R&D Outlay Share – 4.2% of Total Operating Revenue
The company holds 64 USFDA-approved ANDAs, with 52 products actively commercialized across US retail chains and hospital networks. Annual R&D outlays fund complex generic formulation developments and non-infringing process patent filings.
Latest Quarterly Financial Performance of Granules India (Q4 FY26)
Granules India recorded steady top-line growth and operating EBITDA margin expansion during the fourth quarter of FY26.
- Consolidated Revenue from Operations – Rs 1,280.50 crore (+10.2% YoY)
- Consolidated Operating EBITDA – Rs 268.40 crore (+15.8% YoY)
- Consolidated Operating EBITDA Margin – 20.9% (+101 bps YoY)
- Consolidated Net Profit After Tax (PAT) – Rs 142.80 crore (+18.2% YoY)
- Board Recommended Final Dividend – Rs 1.50 per equity share
Fourth-quarter operating turnover expanded 10.2% year-on-year to Rs 1,280.50 crore, supported by finished dosage volume dispatches in the US. Consolidated Net Profit After Tax reached Rs 142.80 crore, with operating EBITDA margins expanding to 20.9%.
Consolidated Annual Financial Performance of Granules India (FY26)
Granules India achieved operating turnover expansion and profit growth for full financial year FY26.
- Full Year Consolidated Revenue from Operations – Rs 4,850.40 crore (+8.5% YoY)
- Full Year Operating EBITDA – Rs 985.20 crore (+12.4% YoY)
- Full Year Operating EBITDA Margin – 20.3% (+71 bps YoY)
- Consolidated Net Profit After Tax (PAT) – Rs 525.40 crore (+14.8% YoY)
- Total Return on Capital Employed (ROCE) – 18.5%
Full-year operating turnover crossed Rs 4,850 crore in FY26, as consolidated Net Profit After Tax reached Rs 525.40 crore. Operational execution was supported by product mix enrichment toward finished dosages and stable raw material input costs.
Balance Sheet Ratios & Capital Structure Metrics of Granules India (Q4 FY26)
Granules India maintains a healthy capital structure supported by strong operating cash generation and controlled debt levels.
- Net Debt to Operating EBITDA Ratio – 0.85x (vs 1.12x in FY25)
- Debt to Equity Ratio – 0.28x
- Return on Equity (ROE) – 16.2%
- Working Capital Cycle – 112 days (compressed by 8 days YoY)
- Cash & Surplus Investments Base – Rs 480 crore
Net debt compressed significantly during Q4 FY26, lowering the Net Debt to EBITDA ratio to 0.85x. Working capital discipline reduced inventory holding days across raw material and finished product stocks.
Capital Expenditure & Green Chemistry Roadmap of Granules India (FY27–FY28)
Granules India executes capital allocation outlays to establish green pharmaceutical manufacturing facilities and expand specialized formulation lines.
- Planned Annual Capital Expenditure – Rs 350–400 crore per annum
- Kakinada Green Polymer & API Project Outlay – Integrated green DCDA and PAP manufacturing plant in Andhra Pradesh
- Capacity Debottlenecking Focus – Expanding active ingredient capacity at Bonthapally and finished dosage lines at Gagillapur
- Funding Strategy – 100% funded through internal operational cash accruals and long-term bank facilities
Annual capex is budgeted at Rs 350–400 crore to construct a green PAP plant in Kakinada and debottleneck Gagillapur tablet lines. Internal operational cash flows fund over 80% of project outlays, maintaining balance sheet discipline.
Management Commentary & Strategic Outlook of Granules India (Q4 FY26 / FY27)
Management guidance highlights strategic priorities centered on core molecule market expansion, non-core generic launches, and backward integration.
- Management targets achieving a 12%–15% revenue CAGR over the FY27–FY29 period.
- Finished dosage segment revenue share is guided to expand toward 60% of total turnover over the next 3 years.
- Consolidated Operating EBITDA margins are guided to sustain within the 20.5%–22.0% corridor through yield improvements.
- Kakinada green chemistry project is scheduled for commercial commissioning in H2 FY27 to secure captive raw material supplies.
- New ANDA filing momentum will target 8–10 filings annually, focusing on controlled substances and modified-release formulations.
Management anticipates steady growth across regulated generic markets, driven by off-patent formulation demand and vertical integration advantages. Operational focus remains on executing the Kakinada green PAP project, scaling specialized formulation launches, and maintaining debt discipline.
Want to filter out stocks using your own financial benchmarks? You can use the Stock Screener on Finology Ticker to identify and compare companies based on specific growth and efficiency metrics.
Sources & References
- Granules India Q4 & Full Year FY26 Consolidated Financial Results Disclosures (May 2026)
- Granules India Q4 FY26 Investor Presentation & Fact Sheet (May 2026)
- Granules India Q4 FY26 Earnings Conference Call Transcript (May 2026)
- BSE India & NSE Official Corporate Announcements for Granules India
- Ticker Finology Granules India Page
Disclaimer
The information presented above on Granules India has been compiled from the company's Annual Reports, Investor Presentations, Earnings Call (Concall) Transcripts, official regulatory filings and the financial data available on Finology Ticker. Certain figures, classifications or comparisons may vary due to differences in accounting policies, reporting methodologies or subsequent restatements by the company. This content is intended solely for informational purposes and should not be considered as investment advice. Investors are advised to refer to the latest company filings and the updated financial data, ratios and disclosures available on this Finology Ticker Granules India page before making any investment decision. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.